Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are ...
That’s how much Eli Lilly’s revenue ... and scale and growth rate.” The Lilly metabolic medicines are still tremendous drivers of revenue. The company expects Mounjaro will tally about ...
Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro ...
Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli Lilly's Mounjaro and Zepbound. The stock (LLY) dropped 8.2% in morning trading, enough to ...
Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, providing some relief to investors after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback